Impact of Dapagliflozin on Heart Failure with Reduced Ejection Fraction: A Real-World Study.
Dapagliflozin 對射血分率降低型心衰竭的影響：一項真實世界研究
J Clin Pharmacol 2025-07-23
Sodium-Glucose Cotransporter 2 Inhibitors and Stroke Risk in Patients with Diabetes and Stroke Risk Factors: A Real-World Cohort Study.
Sodium-Glucose Cotransporter 2 抑制劑對於具有糖尿病及中風危險因子的患者之中風風險：一項真實世界世代研究
Int J Stroke 2025-07-23
Contemporary medical therapy, sex-specific characteristics, and outcomes of patients with non-ischemic cardiomyopathy: a prespecified interim analysis of the BIO-LIBRA study.
非缺血性心肌病患者的現代藥物治療、性別特異性特徵與預後：BIO-LIBRA 研究的預先規劃期中分析
EClinicalMedicine 2025-07-23
Sodium-glucose co-transporter 2 inhibitors improve insulin resistance and β-cell function in type 2 diabetes: A meta-analysis.
Sodium-glucose co-transporter 2 抑制劑可改善第二型糖尿病的胰島素阻抗與β細胞功能：一項統合分析
World J Diabetes 2025-07-23
Sodium-Glucose Cotransporter 2 Inhibitors Use in Patients With Liver Cirrhosis.
Sodium-Glucose Cotransporter 2 抑制劑在肝硬化患者中的使用
Diabetes Metab Res Rev 2025-07-23
Association of antidiabetic medications with psychiatric disorders in patients with type 2 diabetes: a cross-sectional study.
第二型糖尿病患者使用抗糖尿病藥物與精神疾病之關聯性：一項橫斷面研究
Eur J Med Res 2025-07-22
Effect of sodium-glucose cotransporter 2 inhibitors on ventricular function in systemic right ventricular failure.
SGLT2 抑制劑對系統性右心室衰竭患者心室功能的影響
Open Heart 2025-07-22
對有systemic right ventricle（sRV）衰竭的成人來說，使用SGLT2抑制劑後，前50天內心臟功能有明顯進步，之後一年則維持穩定。但如果有做subpulmonary left ventricular pacing，初期雖然有改善，後續心臟功能反而會變差，顯示pacing可能對sRV有負面影響。整體來說，SGLT2抑制劑對sRV衰竭短期內是有幫助的。
相關文章PubMedDOI推理
Empagliflozin does not prevent progression of Dent's disease type 1 in a mouse model.
Empagliflozin 無法預防 Dent’s disease type 1 在小鼠模型中的進展
Exp Physiol 2025-07-22
研究發現，雖然empagliflozin能降低Dent’s disease type 1小鼠的腎小管損傷指標（LCN2），但對蛋白尿、高鈣尿、發炎、纖維化及腎功能惡化等主要症狀都沒有效果，無法預防疾病惡化成慢性腎臟病。
相關文章PubMedDOI推理
SGLT2 INHIBITORS: FROM GLYCEMIC CONTROL TO CARDIO-RENAL PROTECTION EVLOEV KHARON KH1*, SNITSA DANIIL V2, PANKOV DANIL S2, GASPARYAN MARIYA A1, ZAYCEV MATVEY V3, KOIFMAN NATALYA A1, BUGLO ELENA A4, ZEFIROVA MARGARITA S2, RACHKOVA TAMARA A2, GURTIEV DMITRII A1, ZASEEVA VICTORIA V1, TOLMASOV JALOLIDDIN M1. 1NORTH-WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I.I. MECHNIKOV, SAINT-PETERSBURG, RUSSIA. 2SAINT-PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY, SAINT-PETERSBURG, RUSSIA. 3PAVLOV FIRST SAINT-PETERSBURG STATE MEDICAL UNIVERSITY, SAINT-PETERSBURG, RUSSIA. 4INSTITUTE OF MEDICAL EDUCATION, ALMAZOV NATIONAL RESEARCH CENTRE, SAINT-PETERSBURG, RUSSIA. ABSTRACT. SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS WERE ORIGINALLY DEVELOPED AS GLUCOSE-LOWERING AGENTS FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM). HOWEVER, A GROWING BODY OF ROBUST CLINICAL EVIDENCE HAS DEMONSTRATED THEIR PROFOUND CARDIOPROTECTIVE AND NEPHROPROTECTIVE EFFECTS THAT EXTEND BEYOND GLYCEMIC CONTROL. THIS REVIEW SUMMARIZES THE CURRENT UNDERSTANDING OF THE MECHANISMS UNDERLYING THESE BENEFITS AND THE CLINICAL IMPLICATIONS ACROSS A WIDE RANGE OF PATIENT POPULATIONS. WE DISCUSS LANDMARK CARDIOVASCULAR AND RENAL OUTCOME TRIALS, EVALUATE THE PHYSIOLOGICAL AND MOLECULAR MECHANISMS, INCLUDING HEMODYNAMIC MODULATION, ANTI-INFLAMMATORY AND ANTIFIBROTIC EFFECTS, AND IMPROVEMENTS IN MYOCARDIAL AND RENAL ENERGETICS, AND ASSESS THE ROLE OF SGLT2 INHIBITORS IN HEART FAILURE WITH REDUCED AND PRESERVED EJECTION FRACTION, AS WELL AS IN CHRONIC KIDNEY DISEASE WITH AND WITHOUT DIABETES. THE TRANSLATION OF THESE FINDINGS INTO CLINICAL GUIDELINES HAS RESHAPED THERAPEUTIC STRATEGIES IN BOTH ENDOCRINOLOGY AND CARDIOLOGY, UNDERSCORING THE IMPORTANCE OF SGLT2 INHIBITORS AS A CORNERSTONE IN CARDIORENAL PROTECTION.
SGLT2 抑制劑：從血糖控制到心腎保護
Georgian Med News 2025-07-22